Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536846 · ClinicalTrials.gov registry record · Phase 4
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
A Phase 4 study of Healthy, sponsored by Dost Ongur.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT02536846: Completed Phase 4 study of Healthy, sponsored by Dost Ongur.
NCT02536846 is a Phase 4 study of Healthy that has completed, run by Dost Ongur. The registered enrollment target is 35 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02536846, a Phase 4 study of Healthy, has completed, sponsored by Dost Ongur.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
Primary Outcome
Change in brain nicotinamide adenine dinucleotide NAD+/NADH metabolite ratio as measured by in vivo 31P magnetic resonance spectroscopy
Conditions Studied
Interventions
- DRUG Olanzapine
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2019-11-08 |
| Phase | Phase 4 |
What the finished NCT02536846 record still lists
NCT02536846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Olanzapine is the first listed.
NCT02536846 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02536846 about?
NCT02536846 is a clinical study titled "The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals". The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
What is the current status of trial NCT02536846?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2017-11-17. Estimated completion is 2019-11-08.
What conditions does trial NCT02536846 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02536846?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT02536846?
This trial is sponsored by Dost Ongur, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02536846 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02536846's enrollment target sits among peer trials
35 623rd of 1090 higher than 461 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI